Donanemab for Early Cognitive Decline with Lewy Bodies
Treatments studied
Part of Brain & nervous system, Hormones & metabolism, Mental health clinical trials.
This study tests donanemab, an investigational drug designed to target amyloid proteins in the brain that may contribute to cognitive decline in people with early dementia with Lewy bodies. The trial aims to see if this treatment can slow cognitive decline and help preserve thinking and memory.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Gradual worsening of thinking or memory lasting at least 6 months
- At least one symptom of dementia with Lewy bodies (such as visual hallucinations, movement problems, or sleep issues)
- Pass a cognitive assessment (MoCA score of 20 or higher)
- Show specific protein markers in blood and spinal fluid indicating brain amyloid and alpha-synuclein pathology
- Have a trusted family member or caregiver willing to participate and help monitor you throughout the study
- Be able to safely undergo MRI and PET brain scans and a spinal tap
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests whether ambroxol can act as a “disease-modifying” treatment for Lewy body dementia, meaning it aims to change how the illness progresses rather than only relieve symptoms. You may be asked to complete brain testing and have stable medications while the study monitors memory, thinking, and safety.
This study helps people understand a protein called alpha-synuclein that may be related to memory problems and movement disorders. Researchers will either test your spinal fluid or skin to look for this protein, then discuss the results with you and measure how you're doing over time.
This is a follow-up study for people who already completed a previous donanemab trial (AACM). Donanemab is a medication designed to slow cognitive decline in early Alzheimer's disease by targeting amyloid buildup in the brain.
This trial tests a drug called donanemab in people who have early signs of Alzheimer's disease (amyloid buildup in the brain) but are still thinking clearly. The goal is to see if the drug can slow or prevent cognitive decline before memory problems start.
This study compares donanemab plus usual care to usual care alone for people with early Alzheimer's symptoms, to see how well donanemab works in everyday life. You may be able to join if you have early memory or thinking problems and have a brain scan or blood test showing Alzheimer's-related changes.
This trial tests whether a monoclonal antibody (a type of medicine that targets amyloid, a protein that builds up in the brain) can help people who have both Parkinson's disease and early signs of memory problems or dementia. The study uses brain imaging to confirm amyloid buildup before enrolling patients.
Hear when a new Cognitive Dysfunction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.